[Bolus administration of XXXX for preventing the haemodynamic response to tracheal intubation: a multicentre clinical study].

@entity1 @entity1219 @entity591 @entity7368 @entity19496 @entity551 @entity1168
OBJECTIVE: To explore the dose-response relation and the safety of @entity7368 administered as a single i.v. bolus prior to the induction of anesthesia for preventing the haemodynamic response to tracheal intubation. METHODS: 1,830 @entity1 from 20 centres were randomly divided into three groups: E1 group, receiving @entity7368 at a dose of 1 mg/kg; @entity19496 mg/kg and E0 group, receiving 0.9% @entity1219 . Heart rate, @entity551 (MAP) were measured following the induction and 1 to 10 minutes following the intubation. RESULTS: The @entity1 in the E0 group had greater HR and MAP values after anesthesia induction and tracheal intubation than the @entity1 in the E1 and E2 groups (P < 0.05-0.01). The E1 group had higher HR than the E2 group (P < 0.05-0.01). The incidence of @entity591 after intubation was higher in the E0 group (63.8%) than in the E1 group (34.7%) and the E2 group (22.6%) (P < 0.01). The proportion of hypotention and @entity1168 was higher in the two treatment groups than the E0 group (P < 0.01), but no severe adverse event was observed. CONCLUSION: A 1-2 mg/kg bolus of @entity7368 is effective and safe for preventing the haemodynamic response to tracheal intubation. The clinical and side-effects are all dose-related.
